Glaukos (GKOS)
(Delayed Data from NYSE)
$141.75 USD
+2.42 (1.74%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $141.98 +0.23 (0.16%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$141.75 USD
+2.42 (1.74%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $141.98 +0.23 (0.16%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
Zacks News
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 46.15% and 5.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
by Zacks Equity Research
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism.
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?
by Zacks Equity Research
GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
Glaukos Stocks Rides on Strong Product Demand Amid Competition
by Zacks Equity Research
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
by Zacks Equity Research
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 0% and 8.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
by Indrajit Bandyopadhyay
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.
Strength Seen in CVRx (CVRX): Can Its 19.0% Jump Turn into More Strength?
by Zacks Equity Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?
by Zacks Equity Research
Shares of Baxter (BAX) are showing signs of stability after falling in the first half of 2024. Let's see what is driving investors' sentiment for the company.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.